Goldwasser Meredith has filed 4 insider transactions across 1 company since March 2023.
Most recent transaction: a grant/award of 90500 shares of Prime Medicine, Inc. ($PRME) on February 27, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 27, 2025 | Prime Medicine, Inc. | $PRME | Goldwasser Meredith | SVP, Strategy & Corporate Ops. | A | Stock Option (right to buy) | 90500 | $0.00 | 90,500.0000 | 131,160,842 | 9999.99% | 0.07% |
| Feb. 21, 2024 | Prime Medicine, Inc. | $PRME | Goldwasser Meredith | SVP, Strategy & Corporate Ops. | A | Stock Option (right to buy) | 90498 | $0.00 | 90,498.0000 | 0 | 9999.99% | 0.00% |
| April 18, 2023 | Prime Medicine, Inc. | $PRME | Goldwasser Meredith | SVP, Strategy & Corporate Ops. | A | Stock Option (right to buy) | 4690 | $0.00 | 4,690.0000 | 0 | 9999.99% | 0.00% |
| March 31, 2023 | Prime Medicine, Inc. | $PRME | Goldwasser Meredith | SVP, Strategy & Corporate Ops. | A | Stock Option (right to buy) | 90498 | $0.00 | 90,498.0000 | 0 | 9999.99% | 0.00% |